TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Use of rescue analgesic
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Event rate at 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Symmetry index (SI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximum concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to maximum CNS dopamine transporter occupancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Changes in the posteromedial direction of both limbs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of the right limb
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of mild adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: mean percentage healing at D28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean number of meshes used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Colonic motility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Incidence rate of diarrhea of grade 1 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence rate of hand-foot syndrome (HFS) of grade 1 or higher
Endpoint domain: Adverse events/effects
Primary endpoint: LnVO2Endur
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hematoma growth prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anticipated pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anticipated pain unpleasantness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ki-67+ epithelial cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EG-2+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in biochemical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side effects reported by patients
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of severe symptomatic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Quality-adjusted time without symptoms of disease or adverse events (Q-TWiST)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Overall RDQ symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall treatment response
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Breast-milk choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Plasma choline concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: PSA decline of 50%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of students who are overweight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 5F-Wellness-AF score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: ALPS score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Weight control behaviors (WCB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: overall survival rate at 3 months
Endpoint domain: Mortality/survival
Primary endpoint: cumulative progression-free survival rate during the first 15 months
Endpoint domain: Mortality/survival
Primary endpoint: cumulative event-free survival rate during the first 15 months
Endpoint domain: Mortality/survival
Primary endpoint: TNF production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 30-day composite of death, myocardial infarction, stroke, acute aortic regurgitation, and BARC bleeding ≥3
Endpoint domain: Mortality/survival
Primary endpoint: 50% reduction in the mean echocardiographic trans‐aortic gradient
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: incidence of moderate/severe renal function worsening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prediction of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardio- and cerebrovascular morbidity and mortality
Endpoint domain: Mortality/survival
Primary endpoint: adhesive failure at enamel margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RCS change score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PASS estimate for RCS
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean change in Northwick Park score at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HRS6 area under the curve for predicting likelihood of cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Vascular deaths
Endpoint domain: Mortality/survival
Primary endpoint: Major hemorrhages
Endpoint domain: Adverse events/effects
Primary endpoint: One-year completion rate
Endpoint domain: Mortality/survival
Primary endpoint: percentage of 24-h recording with gastric pH >4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: mean acidity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gastric emptying (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom score for gastric distension
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Symptom score for bloating
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time to Clinical Stability (TCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: kilocalories consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Self-Skin Examinations (SSEs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of new melanomas
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Significant prostate cancer at RP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Diminished progression of intrathecal morphine dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kujala scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Surgical morbidity (femoral-based tenderness)
Endpoint domain: Adverse events/effects
Primary endpoint: Patellar stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of grade 3 to 5 nonhematologic adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: TXB2 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate of H. pylori
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Time taken for catheter placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of vascular punctures
Endpoint domain: Adverse events/effects
Primary endpoint: Change in mean frequency of headaches per 30 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in headache severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Verbal fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of adequate vaccine response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: geometric mean titer rises
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Delayed developmental muscular acquisitions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of serum cholesterol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to rehospitalization or death
Endpoint domain: Mortality/survival
Primary endpoint: Mean rehospitalization rates per patient
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Inflammatory processes in the airway epithelium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in number of drinks consumed per week
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients no longer exceeding low-risk drinking limits
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of fasciculations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of α‐GST at 0.5 h after resection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Heart Rate (HR) at first minute of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen Saturation (SpO2) at first minute of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Greater persistence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: More confidence to use flare coping solutions
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: AUC0-inf values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C max values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in behavioral distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent satisfaction with pain management
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma remifentanil concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faecal bifidobacterial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Falls prevented
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Increment in energy expenditure from sitting to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Body-ideal internalization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle dysmorphia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PC(20) values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: eNO values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: rate of serious incident lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: SF-36 Global Health Status (GHS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fibromyalgia Impact Questionnaire total score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fibromyalgia Impact Questionnaire pain score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Fibromyalgia Impact Questionnaire fatigue score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall satisfaction with golimumab injection experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Recovery time to extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery time to standing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of recovery
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Weight loss target achievement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antimicrobial prescribing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: headache relief at 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of wound complications
Endpoint domain: Adverse events/effects
Primary endpoint: quality of scarring (POSAS and VAS scores)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: ADHD symptom severity
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Body mass index (BMI) change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prolactin level change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Two-year target lesion revascularization (TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sIgA concentration change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reduction of stress level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Glycemic response to a 75-g oral glucose load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Plasma levels of total cholesterol, LDL cholesterol, apoB, and LDL-apoB
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visceral adipose tissue accumulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Utilization rates of dental care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Annual visits per person
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Costs of dental care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: prolonged benefit
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of risky drinkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in central retinal thickness (CR/LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in best-corrected visual acuity (BCVA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of bronchial asthma (BA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Global aesthetic improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: RPP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: performance impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subjective sensations after intake
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of progression of renal failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Patient satisfaction with pharmaceutical care model
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Knowledge scores in treatment patients
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Problems with sexual function
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of patients reaching target daily steps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caloric goal achievement on day of weaning from ventilator
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Caloric goal achievement on day of tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Nighttime and daytime asthma symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morning PEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post‐bronchodilator forced expiratory volume in 1 s
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration of antibiotic exposure
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of patients using antibiotics for ≥5 days
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite harm endpoint (death, rehospitalization, ICU admission)
Endpoint domain: Adverse events/effects
Primary endpoint: Muscle hardness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain intensity (VAS score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: success rate of insertion at the first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate cancer specific survival
Endpoint domain: Mortality/survival
Primary endpoint: Risk of cardiovascular deaths
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in ulceration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Reduction of patient's pain scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Amplitude of recorded EMG signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spectral power in the frequency range 0-20 Hz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in histological activity index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of preterm birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: average duration of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Apgar score at 5 minutes of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Time to first embolic signals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in angina
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decreased glyceryl trinitrate usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Radial glenoid inclination on the AP view
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radioulnar variance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of postoperative adhesion formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Farnsworth–Munsell D100 total error score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of residents with a pain complaint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in pain management
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HbA1c lowering
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: correct answers in the 10-15 minute vigilance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: subtraction test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived benefit of rivastigmine
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Beneficial effects of Hypericum extracts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total fraction of time (pH < 4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: sVCAM‐1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: sE‐selectin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reasoning performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of processing performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ultra-distal areal BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: trabecular vBMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean serum folate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean tHcy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Use of rescue beta 2-agonist
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Compliance with study drug
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SPADI score reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Schirmer test result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total cost per participant
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Improvement in total cholesterol and LDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: uncooperative behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes